Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer

First results from LIGHTHOUSE trial presented at 23rd Annual Scientific Meeting in Urologic Oncology (SUO) 

Related Keywords

Germany ,San Diego ,California ,United States ,Munich ,Bayern ,Texas ,Scintomics Gmb ,Davide Gauden ,Brianf Chapin , ,Technical University Of Munich ,Division Of Surgery ,University Of Texas Md Anderson Cancer Center ,Department Of Urology ,Drug Administration ,Study Group ,Blue Earth Diagnostics ,Prostate Specific Membrane Antigen Targeted ,Annual Scientific Meeting ,Urologic Oncology ,Associate Professor ,Cancer Center ,Coordinating Investigator ,New Drug Application ,Chief Executive Officer ,Blue Earth ,Earth Diagnostics ,Efficacy Analysis Population ,Safety Population ,Emission Tomography ,Newly Diagnosed Prostate Cancer ,Multicenter Study ,Radiohybrid Prostate Specific Membrane Antigen ,Technical University ,Scintomics Gmbh ,